Evaluation of the Correlation Between Hemoglobin, Albumin, Lymphocyte, and Platelet Score and Prognosis in Patients with Mantle Cell Lymphoma: Single Center Retrospective Study

Objective: Mantle cell lymphoma (MCL) is a rare and aggressive subtype of B-cell non-Hodgkin lymphoma, representing 3-10% of cases, with a poor prognosis (median survival of 4-5 years). The role of the hemoglobin, albumin, lymphocyte, and platelet (HALP) score in MCL patients is not well understood. This study aims to assess the prognostic value of the initial HALP score in predicting overall survival (OS) and progression-free survival (PFS) in MCL patients. Material and Methods: We conducted a retrospective analysis of 139 MCL patients diagnosed from 2016 to 2023 at Ege University's Hematology Clinic. Data collected included demographic and clinical factors, the International Prognostic Index for MCL (MIPI) risk score, hematological indices, and HALP score, calculated as: [hemoglobin (g/dL)×albumin (g/dL)×lymphocyte count (/L)/platelet count (/L)]. OS and PFS were analyzed using Kaplan-Meier survival curves and multivariate Cox regression. Results: The mean age of the cohort was 65.27 years, with 89.2% diagnosed at advanced stages. Patients were grouped according to median values for the HALP score and PFS and OS were not statistically significant according to HALP score. Median OS was 59.7 months, influenced by age, disease stage, and MIPI classification. Advanced stage [hazard ratio (HR): 3.67, p=0.031] and high MIPI risk (HR: 2.56, p=0.021) were significant predictors of mortality, while autologous hematopoietic stem cell transplantation reduced mortality risk (HR: 0.52, p=0.041). Conclusion: The HALP score may enhance prognosis in MCL, particularly with elevated white blood cell counts; further research is needed to validate these findings.